Availability of Long-Acting Injectable Buprenorphine at Substance Use Treatment Facilities in 2021

Nitin Vidyasagar; Samuel R Bunting; Vineet M Arora; Mim Ari

doi:10.1001/jama.2023.26522

Availability of Long-Acting Injectable Buprenorphine at Substance Use Treatment Facilities in 2021

JAMA. 2024 Feb 13;331(6):524-526. doi: 10.1001/jama.2023.26522.

Authors

Nitin Vidyasagar¹, Samuel R Bunting², Vineet M Arora¹, Mim Ari³

Affiliations

¹ Pritzker School of Medicine, The University of Chicago, Chicago, Illinois.
² Department of Psychiatry & Behavioral Neuroscience, The University of Chicago, Chicago, Illinois.
³ Department of Medicine, The University of Chicago, Chicago, Illinois.

No abstract available

Plain language summary

This study assesses the proportion of US substance use and mental health care facilities that offered any medications for opioid use disorder and, specifically, long-acting injectable buprenorphine in 2021.

MeSH terms

Analgesics, Opioid / therapeutic use
Buprenorphine* / administration & dosage
Buprenorphine* / supply & distribution
Buprenorphine* / therapeutic use
Delayed-Action Preparations
Health Facilities / statistics & numerical data
Humans
Injections
Naltrexone / therapeutic use
Narcotic Antagonists* / administration & dosage
Narcotic Antagonists* / supply & distribution
Narcotic Antagonists* / therapeutic use
Opiate Substitution Treatment
Opioid-Related Disorders* / drug therapy
Substance-Related Disorders / drug therapy
United States / epidemiology

Substances

Analgesics, Opioid
Buprenorphine
Naltrexone
Narcotic Antagonists
Delayed-Action Preparations